{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T15:21:43Z","timestamp":1720106503929},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1097\/cji.0b013e31818c8aaf","type":"journal-article","created":{"date-parts":[[2008,12,18]],"date-time":"2008-12-18T08:39:47Z","timestamp":1229589587000},"page":"79-85","source":"Crossref","is-referenced-by-count":6,"title":["A Phase 1 Study of Granulocyte Macrophage Colony-stimulating Factor (Sargramostim) and Escalating Doses of Thalidomide in Patients With High-risk Malignant Melanoma"],"prefix":"10.1097","volume":"32","author":[{"given":"Jose","family":"Lutzky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Weber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne","family":"Nunez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matt","family":"Gillett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynn","family":"Spitler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-9-20210208","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3322\/CA.2007.0010","article-title":"Cancer statistics, 2008","volume":"58","author":"Jemal","year":"2008","journal-title":"CA Cancer J Clin"},{"key":"R2-9-20210208","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3322\/canjclin.54.3.131","article-title":"An evidence-based staging system for cutaneous melanoma","volume":"54","author":"Balch","year":"2004","journal-title":"CA Cancer J Clin"},{"key":"R3-9-20210208","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/0002-9610(87)90600-3","article-title":"Effect of surgical treatment on stage IV melanoma","volume":"153","author":"Hena","year":"1987","journal-title":"Am J Surg"},{"key":"R4-9-20210208","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1002\/1097-0142(19850901)56:5<1222::AID-CNCR2820560544>3.0.CO;2-A","article-title":"Surgical treatment of distant metastatic melanoma. Indications and results","volume":"56","author":"Overett","year":"1985","journal-title":"Cancer"},{"key":"R5-9-20210208","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1586\/14737140.2.5.547","article-title":"Noninterferon-based adjuvant therapy for high-risk melanoma","volume":"2","author":"Spitler","year":"2002","journal-title":"Expert Rev Anticancer Ther"},{"key":"R6-9-20210208","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1200\/JCO.2000.18.8.1614","article-title":"Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor","volume":"18","author":"Spitler","year":"2000","journal-title":"J Clin Oncol"},{"key":"R7-9-20210208","first-page":"4086","article-title":"Differential effect of recombinant granulocyte macrophage colony-stimulating factor on human monocytes and alveolar macrophages","volume":"49","author":"Thomassen","year":"1989","journal-title":"Cancer Res"},{"key":"R8-9-20210208","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00002371-199404000-00008","article-title":"Monocyte activation following systemic administration of granulocyte-macrophage colony-stimulating factor","volume":"15","author":"Chachoua","year":"1994","journal-title":"J Immunother Emphasis Tumor Immunol"},{"key":"R9-9-20210208","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1182\/blood.V73.3.643.643","article-title":"Recombinant human granulocyte\/macrophage colony-stimulating factor enhances monocyte cytotoxicity and secretion of tumor necrosis factor alpha and interferon in cancer patients","volume":"73","author":"Wing","year":"1989","journal-title":"Blood"},{"key":"R10-9-20210208","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1126\/science.3083507","article-title":"Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor","volume":"232","author":"Grabstein","year":"1986","journal-title":"Science"},{"key":"R11-9-20210208","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S0092-8674(00)81926-1","article-title":"Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma","volume":"88","author":"Dong","year":"1997","journal-title":"Cell"},{"key":"R12-9-20210208","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1084\/jem.182.4.1111","article-title":"Identification of dendritic cell colony-forming units among normal human CD34+ bone marrow progenitors that are expanded by c-kit-ligand and yield pure dendritic cell colonies in the presence of granulocyte\/macrophage colony-stimulating factor and tumor necrosis factor alpha","volume":"182","author":"Young","year":"1995","journal-title":"J Exp Med"},{"key":"R13-9-20210208","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1084\/jem.187.11.1885","article-title":"Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset","volume":"187","author":"Haslett","year":"1998","journal-title":"J Exp Med"},{"key":"R14-9-20210208","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","article-title":"Thalidomide is an inhibitor of angiogenesis","volume":"91","author":"D'Amato","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"R15-9-20210208","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1006\/exer.1997.0292","article-title":"Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization","volume":"64","author":"Kenyon","year":"1997","journal-title":"Exp Eye Res"},{"key":"R16-9-20210208","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1054\/bjoc.1999.1004","article-title":"Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer","volume":"82","author":"Eisen","year":"2000","journal-title":"Br J Cancer"},{"key":"R17-9-20210208","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1200\/JCO.2000.18.13.2593","article-title":"Activity of thalidomide in AIDS-related Kaposi's sarcoma","volume":"18","author":"Little","year":"2000","journal-title":"J Clin Oncol"},{"key":"R19-9-20210208","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J Clin Oncol"},{"key":"R20-9-20210208","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1002\/cncr.21081","article-title":"Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study","volume":"103","author":"Hwu","year":"2005","journal-title":"Cancer"},{"issue":"suppl","key":"R21-9-20210208","first-page":"232s","article-title":"Neoadjuvant GM-CSF and thalidomide in men with high-risk prostate carcinoma undergoing radical prostatectomy (abstract 4564)","volume":"24","author":"Garcia","year":"2006","journal-title":"J Clin Oncol"},{"key":"R23-9-20210208","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1158\/1078-0432.CCR-1103-3","article-title":"A pooled analysis of Eastern Cooperative Oncology Group and Intergroup trials of adjuvant high-dose interferon for melanoma","volume":"10","author":"Kirkwood","year":"2004","journal-title":"Clin Cancer Res"},{"key":"R24-9-20210208","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0305-7372(03)00074-4","article-title":"Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials","volume":"29","author":"Wheatley","year":"2003","journal-title":"Cancer Treat Rev"},{"key":"R25-9-20210208","first-page":"725","article-title":"Phase I\/II study of GM-CSF and thalidomide in patients with high-risk malignant melanoma (abstract 2916)","volume":"22","author":"Lutzky","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"R26-9-20210208","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/jnci\/89.15.1138","article-title":"Accelerated titration designs for phase I clinical trials in oncology","volume":"89","author":"Simon","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"R27-9-20210208","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"R28-9-20210208","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1002\/cncr.22239","article-title":"Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102)","volume":"107","author":"Krown","year":"2006","journal-title":"Cancer"},{"key":"R29-9-20210208","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1002\/cncr.23035","article-title":"Evaluation of interferon alpha-2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026","volume":"110","author":"Hutchins","year":"2007","journal-title":"Cancer"},{"key":"R30-9-20210208","doi-asserted-by":"crossref","first-page":"484s","DOI":"10.1200\/jco.2008.26.15_suppl.9007","article-title":"Phase II trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma; Southwest Oncology Group S0508. (abstract 9007)","volume":"26","author":"Clark","year":"2008","journal-title":"J Clin Oncol"},{"key":"R31-9-20210208","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1182\/blood.V98.5.1614","article-title":"Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy","volume":"98","author":"Zangari","year":"2001","journal-title":"Blood"},{"key":"R32-9-20210208","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/j.1365-2141.2004.05078.x","article-title":"Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation","volume":"126","author":"Zangari","year":"2004","journal-title":"Br J Haematol"},{"key":"R33-9-20210208","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/ajh.20625","article-title":"Efficacy of prophylactic warfarin for prevention of thalidomide-related deep venous thrombosis","volume":"81","author":"Ikhlaque","year":"2006","journal-title":"Am J Hematol"},{"key":"R34-9-20210208","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1080\/10428190600799631","article-title":"Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism","volume":"47","author":"Miller","year":"2006","journal-title":"Leuk Lymphoma"}],"container-title":["Journal of Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CJI.0b013e31818c8aaf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T20:03:00Z","timestamp":1621886580000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002371-200901000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/cji.0b013e31818c8aaf","relation":{},"ISSN":["1524-9557"],"issn-type":[{"value":"1524-9557","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}